Windlas Biotech Limited’s Board of Directors, in a meeting held on April 17, 2026, approved a proposal to buy back up to 470,000 fully paid-up equity shares. This buyback represents 2.23% of the company’s total paid-up equity share capital at a price of INR 1,000 per share, totaling an outlay of INR 47 Crores. The offer will be conducted via the “Tender Offer” route on a proportionate basis, with Friday, April 24, 2026, fixed as the Record Date to determine eligible shareholders. Notably, the company’s promoters and promoter group have expressed their intention not to participate in this buyback.

Windlas Biotech is a leading Pharmaceutical Contract Development and Manufacturing Organization (CDMO) in India, providing a comprehensive range of CDMO services ranging from product discovery to commercial manufacturing. Throughout 2025, the company focused on expanding its high-growth Injectables segment and strengthening its presence in the domestic trade generics market. In mid-2025, the company reportedly received significant export orders for its Dehradun facility after successfully clearing several international regulatory audits, further diversifying its revenue streams beyond the Indian market.

For the quarter ended December 31, 2025 (the last quarterly result announced prior to this notice), Windlas Biotech reported a steady trajectory in its financial performance. The company’s consolidated revenue stood at approximately INR 172 Crores, representing a 12% YoY growth compared to the same quarter in 2024. Net profit for the quarter reached INR 15.5 Crores, reflecting an 8% growth over the previous year. The company’s investor profile remains robust, featuring interest from notable institutional investors such as ICICI Prudential Mutual Fund and Nippon India Mutual Fund, who have historically maintained stakes in the company.